Chimeric RNA/DNA oligonucleotide-based gene therapy

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Intensive hemodialysis—keeping the faith

Genome-editing Technologies for Gene and Cell Therapy

Propofol-related green urine

Anemia management in chronic kidney disease

Montagna Symposium on Epidermal Stem Cells Oligonucleotide-Directed Gene Correction in Epidermis Kyonggeun Yoon Journal of Investigative Dermatology.

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Mutation of a Nuclear Respiratory Factor 2 Binding Site in the 5′ Untranslated Region of the ADSL Gene in Three Patients with Adenylosuccinate Lyase Deficiency

Intensive hemodialysis—keeping the faith

Progression of renal failure and hypertensive nephrosclerosis

Volume 77, Issue 1, Pages 6-8 (January 2010)

Gene electrotransfer: Potential for gene therapy of renal diseases

Francesco Paolo Schena Kidney International

Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function

Double Heterozygosity for a RET Substitution Interfering with Splicing and an EDNRB Missense Mutation in Hirschsprung Disease Alberto Auricchio, Paola.

A Rare Mutation in the Primer Binding Region of the Amelogenin Gene Can Interfere with Gender Identification Bonnie Shadrach, Mairead Commane, Carol.

Volume 70, Pages S21-S25 (December 2006)

CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles

Volume 54, Issue 5, Pages (November 1998)

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

Different Frequency of Gene Targeting Events by the RNA-DNA Oligonucleotide Among Epithelial Cells Evelyn Santana, Adam E. Peritz, Subramanian Iyer,

Insulin resistance in African Americans

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Genome-editing Technologies for Gene and Cell Therapy

Edmund G. Lowrie Kidney International

Prevention of renal failure: The Malaysian experience

Immunoglobulin light chains in uremia

Blood pressure targets in hemodialysis patients

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Fructose intake as a risk factor for kidney stone disease

A CRISPR Approach to Gene Targeting

Volume 87, Issue 1, Pages (January 2015)

Hetal Parekh-Olmedo, Dimitri Krainc, Eric B Kmiec Neuron

New insights in uremic toxins

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Winfried Siffert Kidney International

Microbiology and outcomes of peritonitis in North America

Nephrology in Latin America, with special emphasis on Brazil

AGEs in foods: Do they play a role in uremia?

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Ken-Ichi Egoshi, Koichiro Akakura, Takaomi Kodama, Haruo Ito

Nephrology Crossword: Glomerulonephritis

Chien-Te Lee, Viet M. Huynh, Li-Wen Lai, Yeong-Hau H. Lien

Brad H. Rovin, Ling Lu, Xiaolan Zhang Kidney International

Homocysteine, renal function, and risk of cardiovascular disease

Peritoneal dialysis in Mexico

Immunity unmasks APOL1 in collapsing glomerulopathy

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Organ transplantation goes to the movies

Atherosclerotic nephropathy

Engineering parathyroid cells to treat secondary hyperparathyroidism

Volume 55, Pages S3-S16 (June 1999)

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 70, Issue 3, Pages (August 2006)

Volume 71, Issue 9, Pages (May 2007)

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Attitudes and predictive factors for live kidney donation: A comparison of live kidney donors versus nondonors Lynn Stothers, William A. Gourlay, Li.

Morphology of the heart and arteries in renal failure

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Chimeric RNA/DNA oligonucleotide-based gene therapy Li-Wen Lai, Yeong-Hau H. Lien Kidney International Volume 61, Issue 1, Pages S47-S51 (January 2002) DOI: 10.1046/j.1523-1755.2002.0610s1047.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Sequence of the normal and CA II (−) alleles and chimeric RNA/DNA oligonucleotide. The site of mutation is underlined. The chimeric oligonucleotide contains 25 homologous DNA residues identical to normal allele and only one bp different from CA II (−) allele. The antisense strand contains five core DNA residues that is flanked by 10 2′-O-methyl RNA residues at each side. A double-hairpin configuration is also included. DNA residues are capitalized, and 2′-O-methyl RNA residues are in lowercase. Kidney International 2002 61, S47-S51DOI: (10.1046/j.1523-1755.2002.0610s1047.x) Copyright © 2002 International Society of Nephrology Terms and Conditions